Md.’s MaxCyte signs commercial licensing agreement with Austrian biotech

Listen to this article

MaxCyte Inc., a Gaithersburg cell-based therapies and life sciences company, signed a clinical and commercial licensing agreement Wednesday with Apeiron Biologics AG, a private biotechnology company specializing in the discovery, development and commercialization of novel immunotherapies for cancer and respiratory diseases.

Apeiron will obtain non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation technology and ExPERT platform for the advancement of APN401, a siRNA-based cell therapy currently in clinical development for various solid tumors. In return, MaxCyte will receive undisclosed development and approval milestones and sales-based payments in addition to other licensing fees.

MaxCyte’s ExPERT instrument portfolio represents the next generation of leading, clinically validated, electroporation technology for complex and scalable cell engineering. By delivering high transfection efficiency, seamless scalability and enhanced functionality, the ExPERT platform delivers the high-end performance essential to enable the next wave of biological and cellular therapeutics.

MaxCyte uses its proprietary next-generation cell and gene therapies to revolutionise medical treatments and ultimately save lives. The company’s cell engineering enabling technology is currently being deployed by leading drug developers worldwide, including all of the top 10 global biopharmaceutical companies.

MaxCyte licenses have been granted to more than 100 cell therapy programs, with more than 70 licensed for clinical use, and the Company has now entered into eleven clinical/commercial license partnerships with leading cell therapy and gene editing developers.